Prostate cancer treatment is the field where "latest technology" marketing is most likely to steer you wrong. Robotic prostatectomy, open prostatectomy, IMRT, SBRT, brachytherapy, proton — the outcomes data across most of these is closer than the marketing suggests, and the biggest lever on your result is the surgeon's (or radiation oncologist's) specific experience with your scenario.
For low-risk localized disease
Active surveillance is underprescribed. Gleason 6 with low PSA and small-volume disease has good outcomes on surveillance alone with regular monitoring. If every doctor you've seen recommends immediate treatment for low-risk disease, get a second opinion from a surveillance-friendly centre before committing to anything.
For intermediate-risk
Robotic and open radical prostatectomy have functionally equivalent cancer-control outcomes at 10 years in randomized data. Robotic has modestly better short-term continence and bleeding; open has no durability disadvantage. The differentiator is surgeon volume: a surgeon doing 100+ prostatectomies a year (robotic or open) has better outcomes than a surgeon doing 20, regardless of technology.
Radiation alternatives — IMRT (external beam) or brachytherapy (seeds) — have similar cancer control with different side-effect profiles. No erectile function advantage from radiation; more urinary irritation early, less incontinence long-term.
For high-risk or locally advanced
Multimodal treatment (radiation + androgen deprivation, sometimes surgery) drives outcomes, not the specific radiation platform. Proton's advantage here is marginal vs photon in the published data.
For metastatic disease
Systemic therapy is the primary driver: androgen deprivation, next-gen hormonal agents (enzalutamide, abiraterone), chemotherapy, and increasingly PSMA-targeted therapy for specific cases. A multidisciplinary tumor board should be directing sequencing.
Destinations
For surgery: India has the highest per-surgeon volumes globally; Germany has complex-case expertise; Singapore and Korea for robotic precision. For proton: Germany, Japan, Korea. For PSMA-targeted therapy: Germany and Australia have the most mature programs. For advanced clinical trials: US, UK, Germany, Korea.
Questions for any program you're considering
- Surgeon-specific annual prostatectomy volume (not the hospital's).
- Continence and potency outcomes at 1 and 2 years — ask for the specific percentage, not a platitude.
- Positive margin rate — stage-matched.
- PSA surveillance protocol post-treatment.
- Access to molecular/genomic profiling (BRCA, MSI-H) that affects systemic therapy options.
Dernière mise à jour : Nos sources et notre relecture
